We are live on ! Find out more
TCM

Tekla Capital Management Portfolio holdings

AUM $2.56B
1-Year Est. Return 18.15%
This Fund
S&P 500
This Quarter Est. Return
+3.64%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$2.91B
AUM Growth
+$61.2M
Cap. Flow
+$64.4M
Cap. Flow %
2.22%
Top 10 Hldgs %
30.43%
Holding
226
New
26
Increased
31
Reduced
48
Closed
30

Top Buys

Rank Stock Value
1
ELV icon
Elevance Health
ELV
+$41M
2
ABT icon
Abbott
ABT
+$37M
3
MRNA icon
Moderna
MRNA
+$32.5M
4
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$29.2M
5
GILD icon
Gilead Sciences
GILD
+$26.5M

Top Sells

Rank Stock Value
1
ALXN
Alexion Pharmaceuticals
ALXN
+$60.5M
2
BDX icon
Becton Dickinson
BDX
+$22.1M
3
HUM icon
Humana
HUM
+$18.1M
4
TECH icon
Bio-Techne
TECH
+$16.1M
5
NVCR icon
NovoCure
NVCR
+$15.2M

Sector Composition

Rank Sector Weight
1 Healthcare 95.75%
2 Real Estate 2.99%
3 Industrials 0.1%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
QURE icon
126
uniQure
QURE
$3.03B
$4.21M 0.14%
125,003
– –
FMTX
127
DELISTED
Forma Therapeutics Holdings, Inc. Common Stock
FMTX
$4.2M 0.14%
149,825
– –
VIR icon
128
Vir Biotechnology
VIR
$1.55B
$4.17M 0.14%
+81,400
New +$4.39M
SNY icon
129
Sanofi
SNY
$102B
$4.03M 0.14%
81,554
– –
ARDX icon
130
Ardelyx
ARDX
$1.24B
$4.02M 0.14%
607,698
– –
ENDP
131
DELISTED
Endo International plc
ENDP
$3.94M 0.14%
531,570
– –
ADUS icon
132
Addus HomeCare
ADUS
$2.12B
$3.94M 0.14%
37,640
– –
JNCE
133
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
$3.93M 0.14%
+382,237
New +$4.19M
TAK icon
134
Takeda Pharmaceutical
TAK
$52.9B
$3.84M 0.13%
210,146
– –
RETA
135
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
$3.81M 0.13%
38,219
– –
ARQT icon
136
Arcutis Biotherapeutics
ARQT
$3.26B
$3.81M 0.13%
+131,633
New +$4.11M
SNN icon
137
Smith & Nephew
SNN
$12.8B
$3.77M 0.13%
99,560
– –
NKTR icon
138
Nektar Therapeutics
NKTR
$2.46B
$3.61M 0.12%
12,029
– –
MREO
139
Mereo BioPharma
MREO
$51.4M
$3.36M 0.12%
+997,290
New +$3.53M
INSM icon
140
Insmed
INSM
$21.4B
$3.35M 0.12%
98,387
– –
NVO
141
Novo Nordisk
NVO
$196B
$3.26M 0.11%
96,812
-33,000
-25% -$1.18M
PHG icon
142
Philips
PHG
$25.9B
$3.25M 0.11%
70,195
– –
BDTX icon
143
Black Diamond Therapeutics
BDTX
$102M
$3.2M 0.11%
+131,990
New +$3.56M
ALKS icon
144
Alkermes
ALKS
$8.33B
$3.17M 0.11%
169,930
– –
HR
145
DELISTED
Healthcare Realty Trust Incorporated
HR
$3.15M 0.11%
104,024
– –
THC icon
146
Tenet Healthcare
THC
$20.4B
$3.14M 0.11%
60,336
-22,400
-27% -$1.13M
MEDP icon
147
Medpace
MEDP
$16.1B
$3.1M 0.11%
18,871
– –
RCM
148
DELISTED
R1 RCM Inc. Common Stock
RCM
$3.05M 0.1%
+123,461
New +$3.26M
XENE icon
149
Xenon Pharmaceuticals
XENE
$6.19B
$2.97M 0.1%
+165,898
New +$2.81M
TECH icon
150
Bio-Techne
TECH
$11.2B
$2.9M 0.1%
30,400
-176,440
-85% -$16.1M
4 5
6
7 8

Similar funds

EST
EA Series Trust Havertown, Pennsylvania $2.84B AUM
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return
AWS
AJ Wealth Strategies New York $2.07B AUM 10.86% 1-Year Est. Return
JP
Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return
VCM
Vigilant Capital Management Portland, Maine $1.34B AUM 15.33% 1-Year Est. Return
FCFS
First Command Financial Services Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
FCB
First Command Bank Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
BWM
BerganKDV Wealth Management Bloomington, Minnesota $1,000M AUM 9.95% 1-Year Est. Return

Tekla Capital Management's Q1 2021 Portfolio in Review

As of Q1 2021, Tekla Capital Management held 226 positions worth $2.91B, up 2.1% from $2.85B the previous quarter. Its ten largest holdings account for 30% of the portfolio.

Tekla Capital Management's Q1 2021 filing shows 26 new, 31 increased, 48 reduced and 30 closed positions. Its largest new stake was Universal Health Services: 71,323 shares worth $9.51M. The largest sale was Alexion Pharmaceuticals, an estimated $60.5M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, up from 95% a quarter earlier, followed by Real Estate and Industrials.

  • Tekla Capital Management's largest Q1 2021 buy was Universal Health Services: 71,323 shares worth $9.51M.
  • Tekla Capital Management added most to Elevance Health in Q1 2021, an estimated $41M increase.
  • Tekla Capital Management's biggest Q1 2021 reduction was Alexion Pharmaceuticals, cutting an estimated $60.5M.
  • Tekla Capital Management fully exited NovoCure in Q1 2021, selling an estimated $15.2M.
  • Tekla Capital Management's ten largest holdings make up 30% of its $2.91B portfolio in Q1 2021.
  • Tekla Capital Management opened 26 new positions and closed 30 in Q1 2021.
  • Tekla Capital Management's portfolio value rose 2.1% quarter-over-quarter to $2.91B.

Based on Tekla Capital Management's 13F filing for Q1 2021, filed 14 May 2021.